continuously added. The last one, diffusion-weighted imaging (DWI), first introduced for the evaluation of neurological diseases, has been recently investigated in the assessment of the activity of inflammatory bowel disease [15] [16] [17] . MR molecular imaging and MR spectroscopy are still experimental but extremely promising, due to possibility to analyze and characterize the molecular structure of the inflamed wall. Therefore, MRI has great potentials in characterization of the CD, being able to assess microscopic structural wall changes, including edema and fibrosis, hypervascularity, capillary permeability, diffusion of water molecules, and likely, in the next years, specific molecular abnormalities [15] [16] [17] .
In detecting signs of intestinal inflammation in CD, MRI competes not only with the other available imaging modalities, but with endoscopy too. The mucosal disease, assessable by endoscopy, represents only the tip of the inflammatory process, whereas the mural and extramural disease, detectable with MRI, is the hidden and submerged part of the inflammation. According to recent studies, MRI has shown the same sensitivity of endoscopy in detecting active intestinal inflammation [5] [6] [7] [8] 12] .
Since this Feature Section deals with a clinicalradiological subject, a clinical introduction was included, to review the clinical concept of ''Crohn's disease activity'' [18] and to provide an update on the latest knowledge of the immunological network and the new biologic therapies. Certainly, the concept of CD ''activity'' needs to be further discussed by radiologists and gastroenterologists. There are too many clinical indexes of activity: purely clinical, biological, endoscopic, and his tological ones [19] These and many other open questions will be extensively discussed and they will receive an answer from all clinical and radiological papers contributing to the Feature Section.
In the second and purely radiological part of this session, the actual and future possibilities of MRI in the assessment of CD activity will be reviewed and analyzed.
According to the latest guidelines on imaging of IBD [20] , MRI is already considered a reference examination for the assessment of CD activity, together with clinical indexes, ultrasonography, and endoscopy findings. Clinical-radiological guidelines on IBD are currently under revision and new ones are expected in 2012. Undoubtedly, there are still several points to be outlined and defined. At present there is no ''radiological agreement'' on what should be the best MRI technique and parameters for CD evaluation. Whether the small bowel should be evaluated with enteroclysis or with oral administration of contrast medium, is still under discussion. Moreover, in the assessment of CD, should MRI evaluate the colon or the small bowel only? Current trends are mainly favorable to the oral administration of the contrast agent with consensual assessment of the small intestine and colon, though the final answer will be likely offered only by the clinical daily practice.
Regardless of this discussion on the MRI technique to be used, the radiological part of the section is mainly focused on the MRI analysis and characterization of the inflammatory intestinal changes of CD. Assessment of disease activity, disease characterization, and detection of wall edema and fibrosis are definitely central issues in the management of CD.
The diagnostic value and usefulness of T1-and T2-weighted imaging in the assessment of bowel wall inflammation and in the characterization of Crohn's disease will be specifically analyzed and reviewed in two different papers of the Section [21, 22] . In fact, T1-and T2-weighted parameters can display intestinal wall inflammation, fibrosis and edema in different ways. So far, different morphological and functional parameters, both T1-and T2-weighted, have been tested for the assessment of disease activity including wall thickening, degree of wall Gd-enhancement [3-9, 11, 23], T2 mural signal intensity [2, 3, 9, 12, 13], T2 signal of mesenteric fat [2, 9] , enhancement of local lymph nodes [24] , pattern of wall Gd-enhancement [13] , increased mesenteric vascularity [24] , and curves of Gd-wall enhancement (washin and wash-out curves) [8, 10] . Each of these parameters has proved be statistically correlated with the ''biological'', endoscopic, or histological activity [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . The review of these results should clarify the value of both T1-and T2-weighted imaging in the evaluation of disease activity. The availability of multiple imaging parameters is definitely one of the major advantages of MRI, but it may become a limit, if these parameters are not rationally used with proper imaging techniques. The use of too many parameters in a single MRI examination may be disorienting and confusing. On the other hand, an excessive simplification of the MR techniques could reduce the diagnostic capabilities offered by MRI. A rational and conscious use of the proper imaging parameters is the major issue and task for any radiologist involved in intestinal MRI.
The potential role of each one of these MRI parameters in the development of an MRI index of activity will be also extensively discussed in a specific paper [25] . Recently, a magnetic resonance index of activity (MaR-IA) has been proposed [12] , highly correlated with the CDEIS. Other indexes have been preliminarily proposed or are still under development [25, 26] . The possibility of an MRI index of activity is extremely appealing, although still to validate with multicenter studies and a consensus conference.
Furthermore, the possibility of a computerized analysis of disease activity, based on well-defined and quantified parameters, is conceivable. The feasibility potentials and drawbacks of a computer-assisted system for the MRI evaluation of disease activity will be extensively discussed [27] .
Finally, MRI does not offer only T1-and T2-weighted imaging to assess inflammation. New promising imaging parameters, sequences, and techniques have been recently introduced in the clinical practice or are going to be, including real time MRI, diffusion-weighted parameters, spectroscopy, molecular imaging, and PET-MRI [28] . Although the real value of these newest imaging in the evaluation of CD inflammation is still under investigation or has not been tested yet, their potential role will be discussed in the last paper of the Feature Section.
Ideally, the final goal of MRI should be to characterize CD activity to have a prognostic value in therapeutic planning. A guide in the decision making process is more and more needed, due to the complexity of currently available pharmacological options, frequently very focused and targeted against specific pro-inflammatory cytokines. It is conceivable that in the next years the MRI will offer a key for understanding the effects and efficacy of new biological drugs, providing a guide in the choice of the most effective and early treatments [28] .
In conclusion, MRI is certainly a powerful diagnostic tool to assess inflammatory changes in CD. At present, updated MRI systems offer a wide range of imaging parameters to evaluate tissue inflammation. MRI is currently able to analyze and quantify wall vascularity, to differentiate intestinal wall edema and fibrosis, even to detect differences in the motility of water molecules with DWI and metabolic changes by spectroscopy.
Definitely, the potentials of MRI in the detection of CD inflammation are vast, but they can be fully appreciated only at the light of the more recent clinical advances. A strict osmosis between clinical and radiological knowledge will probably be the key of future progresses in clinical-diagnostic research. In the next years, it is expected that radiologists, still maintaining their technical knowledge, will collaborate more and more with gastroenterologists and that, on the other hand, gastroenterologists will be increasingly involved in imaging issues. Likely, the boundaries between clinical and radiological sciences will become less and less defined.
